Previous 10 | Next 10 |
2023-12-27 12:23:36 ET DENVER, Colo., Dec. 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; First Wave BioPharma Inc (NASDAQ: FWBI), Coherus BioSciences Inc (NASDAQ: CHRS), Cingulate Inc (NASDAQ...
2023-12-27 09:57:20 ET DENVER, Colo., Dec. 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; First Wave BioPharma Inc (NASDAQ: FWBI), Coherus BioSciences Inc (NASDAQ: CHRS), Opthea Ltd (NASDAQ: OPT), Ci...
2023-12-27 09:30:08 ET A California-based %Biotech company is stealing the show during Wednesday’s premarket after it was announced that the FDA approved Udenyca Onbody, a device used to deliver Udenyca for cancer patients. According to the release, the company intends to commerc...
2023-12-27 09:25:38 ET DENVER, Colo., Dec 27, 2023 ( www.247marketnews.com )- Coherus BioSciences, Inc. (NASDAQ: CHRS) announced, after yesterday’s market close, that the U.S. Food and Drug Administration (FDA) approved UDENYCA ONBODY, the company’s on-body injector (OBI) ...
2023-12-27 08:27:59 ET First Wave BioPharma FWBI +107% on plans to sell niclosamide program . Cingulate ( CING ) +89% . Cytokinetics CYTK +53% on positive Phase 3 data for heart disease therapy . Jet.AI ( JTAI ) +38% . Cohe...
– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgrastim – REDWOOD CITY, Calif., Dec. 26...
2023-12-24 09:45:00 ET Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport rock-bottom valuations right now. With the Fed possibly set to reverse course o...
2023-12-18 17:21:05 ET Gainers: Xeris Biopharma Holdings ( XERS ) +4% . Intuitive Machines ( LUNR ) +3% . Century Aluminum Company ( CENX ) +3% . Coherus BioSciences ( CHRS ) +2% . Independent Bank ( INDB ) +2% . Losers: ...
– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTORZI monotherapy also recommended as the only preferred regimen in subsequent li...
2023-12-08 08:27:04 ET More on pr-market losers $ stocks. Aditxt appoints Ernie Lee as CEO of its wholly-owned subsidiary, Pearsanta IPO Roundup: WeBuy Global, Maison Solutions and more Seeking Alpha’s Quant Rating on Aditx Therapeutics Historical earn...
News, Short Squeeze, Breakout and More Instantly...
Coherus BioSciences Inc. Company Name:
CHRS Stock Symbol:
NASDAQ Market:
Coherus BioSciences Inc. Website:
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc . (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for up-front all-cash consideration of $40 million. The closing of the tr...
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of ...
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Dayl...